Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Company Overview

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

Key Stats

• Today's Range: C$0.42 to C$0.43
• 50-Day Range: C$0.41 to C$0.66
• 52-Week Range: C$0.41 to C$1.97
• Volume: 31,952 shs
• Average Volume: 106,875 shs
• Market Capitalization: C$35.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 4/30/2026
• Today: 6/22/2026

Industry, Sector and Symbol

• Stock Exchange: TSE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Pharmaceutical Products
• Current Symbol: TSE:MDNA
• CIK: N/A
• Web: www.medicenna.com
• Phone: +1-403-6807898
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): C($0.15)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -C$25.98 million
• Net Margins: -533,640.00%
• Pretax Margin: N/A
• Return on Equity: -103.51%
• Return on Assets: -32.80%

Debt

• Debt-to-Equity Ratio: 3.30
• Current Ratio: 2.68
• Quick Ratio: 4.65

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.37 per share
• Price / Cash Flow: 1.15
• Book Value: C$0.07 per share
• Price / Book: 5.64

Miscellaneous

• Outstanding Shares: 83,420,000
• Free Float: N/A
• Market Cap: C$35.04 million
• Optionable: Not Optionable
• Beta: 2.89